Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial - Summary - MDSpire

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

  • By

  • Lee M. Kaplan

  • Elena Startseva

  • Carel W. le Roux

  • Sean Wharton

  • Biykem Bozkurt

  • Daniel F. Mazo

  • Jessica von Schlippenbach

  • Sandra González Maldonado

  • Samina Ajaz Hussain

  • Guy W. Neff

  • Yaneicy Gonzalez Rojas

  • Charles Smith

  • Ramy Younes

  • Arun J. Sanyal

  • June 7, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy of survodutide in adults with obesity and at-risk MASLD, defined as MASLD with evidence of inflammation and/or fibrosis.

Key Findings:
  • 218 participants with obesity and at-risk MASLD were randomized, with 172 completing the trial, highlighting the dropout rate's implications.
  • Mean age of participants was 55.8 years, with a mean BMI of 39.6 kg/m² and 94.4% having at least one extra-hepatic metabolic complication.
Interpretation:

Survodutide treatment showed potential in improving liver health and weight management in adults with obesity and at-risk MASLD, as evidenced by specific metrics.

Limitations:
  • The trial's duration may not capture long-term effects of survodutide.
  • Participant dropout rates were similar between treatment and placebo groups, which may affect the validity of the results.
Conclusion:

The SYNCHRONIZE-MASLD trial provides insights into the efficacy of survodutide for treating obesity and MASLD, with potential implications for clinical practice.

Original Source(s)

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

  • by Lee M. Kaplan, Elena Startseva, Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Daniel F. Mazo, Jessica von Schlippenbach, Sandra González Maldonado, Samina Ajaz Hussain, Guy W. Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J. Sanyal

  • June 7, 2026

Related Content

Case Report: Hemophagocytic lymphohistiocytosis masquerading as drug-induced liver injury: successful treatment with low-dose ruxolitinib and glucocorticoids

Excluded-stomach Perforation after Roux-en-Y and One-anastomosis Gastric Bypass: A Systematic Review with Video-illustrated Case Report

Targeting macrophages in liver fibrosis